ADMA Biologics, Inc. (ADMA)
Total Valuation
ADMA Biologics has a market cap or net worth of $1.02 billion. The enterprise value is $1.09 billion.
| Market Cap | 1.02B |
| Enterprise Value | 1.09B |
Important Dates
The last earnings date was Wednesday, November 8, 2023, after market close.
| Earnings Date | Nov 8, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 225.97 million shares outstanding. The number of shares has increased by 19.03% in one year.
| Shares Outstanding | 225.97M |
| Shares Change (YoY) | +19.03% |
| Shares Change (QoQ) | +4.97% |
| Owned by Insiders (%) | 2.24% |
| Owned by Institutions (%) | 79.50% |
| Float | 221.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.71 |
| PS Ratio | 4.36 |
| Forward PS | 3.53 |
| PB Ratio | 6.74 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.65 |
| EV / EBITDA | 110.31 |
| EV / EBIT | 632.77 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.54, with a Debt / Equity ratio of 0.94.
| Current Ratio | 6.54 |
| Quick Ratio | 2.52 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | 14.47 |
| Debt / FCF | n/a |
| Interest Coverage | 0.07 |
Financial Efficiency
Return on equity (ROE) is -15.30%.
| Return on Equity (ROE) | -15.30% |
| Return on Assets (ROA) | -6.60% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $379,729 |
| Profits Per Employee | -$36,995 |
| Employee Count | 617 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.10% in the last 52 weeks. The beta is 0.80, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (1Y) | 0.80 |
| 52-Week Price Change | +17.10% |
| 50-Day Moving Average | 3.79 |
| 200-Day Moving Average | 3.72 |
| Relative Strength Index (RSI) | 72.65 |
| Average Volume (30 Days) | 1,913,953 |
Short Selling Information
The latest short interest is 7.81 million, so 3.46% of the outstanding shares have been sold short.
| Short Interest | 7.81M |
| Short Previous Month | 8.70M |
| Short % of Shares Out | 3.46% |
| Short % of Float | 3.52% |
| Short Ratio (days to cover) | 4.85 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $234.29 million and -$22.83 million in losses. Loss per share was -$0.11.
| Revenue | 234.29M |
| Gross Profit | 72.03M |
| Operating Income | 1.34M |
| Pretax Income | -22.83M |
| Net Income | -22.83M |
| EBITDA | 9.88M |
| EBIT | 1.72M |
| Loss Per Share | -$0.11 |
Balance Sheet
The company has $74.16 million in cash and $143.01 million in debt, giving a net cash position of -$68.85 million or -$0.30 per share.
| Cash & Cash Equivalents | 74.16M |
| Total Debt | 143.01M |
| Net Cash | -68.85M |
| Net Cash Per Share | -$0.30 |
| Equity / Book Value | 151.44M |
| Book Value Per Share | 0.67 |
| Working Capital | 231.86M |
Cash Flow
In the last 12 months, operating cash flow was -$16.18 million and capital expenditures -$7.32 million, giving a free cash flow of -$23.50 million.
| Operating Cash Flow | -16.18M |
| Capital Expenditures | -7.32M |
| Free Cash Flow | -23.50M |
| FCF Per Share | -$0.10 |
Margins
Gross margin is 30.74%, with operating and profit margins of 0.57% and -9.74%.
| Gross Margin | 30.74% |
| Operating Margin | 0.57% |
| Pretax Margin | -9.74% |
| Profit Margin | -9.74% |
| EBITDA Margin | 4.22% |
| EBIT Margin | 0.74% |
| FCF Margin | -10.03% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -2.23% |
| FCF Yield | -2.30% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.03% |
| Shareholder Yield | -19.03% |
Analyst Forecast
The average price target for ADMA Biologics is $5.67, which is 25.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.67 |
| Price Target Difference | 25.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 18.72% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 2.63 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.63 |
| Piotroski F-Score | 4 |